Anniina Färkkilä
Anniina Färkkilä
University of Helsinki and Helsinki University Hospital
Verified email at - Homepage
Cited by
Cited by
Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma
PA Konstantinopoulos, S Waggoner, GA Vidal, M Mita, JW Moroney, ...
JAMA oncology 5 (8), 1141-1149, 2019
The Fanconi anemia pathway in cancer
J Niraj, A Färkkilä, AD D'Andrea
Annual review of cancer biology 3, 457-478, 2019
Vascular endothelial growth factor-C accelerates diabetic wound healing
A Saaristo, T Tammela, A Fārkkilā, M Kärkkäinen, E Suominen, ...
The American journal of pathology 169 (3), 1080-1087, 2006
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer
A Färkkilä, DC Gulhan, J Casado, CA Jacobson, H Nguyen, ...
Nature communications 11 (1), 1459, 2020
A first-in-class polymerase theta inhibitor selectively targets homologous-recombination-deficient tumors
J Zhou, C Gelot, C Pantelidou, A Li, H Yücel, RE Davis, A Färkkilä, ...
Nature cancer 2 (6), 598-610, 2021
Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial
PA Konstantinopoulos, SC Cheng, AEW Hendrickson, RT Penson, ...
The Lancet Oncology 21 (7), 957-968, 2020
The CHK1 inhibitor prexasertib exhibits monotherapy activity in high-grade serous ovarian cancer models and sensitizes to PARP inhibition
K Parmar, BS Kochupurakkal, JB Lazaro, ZC Wang, S Palakurthi, ...
Clinical Cancer Research 25 (20), 6127-6140, 2019
A functional homologous recombination assay predicts primary chemotherapy response and long-term survival in ovarian cancer patients
M Tumiati, S Hietanen, J Hynninen, E Pietilä, A Färkkilä, K Kaipio, ...
Clinical Cancer Research 24 (18), 4482-4493, 2018
Pathogenesis and treatment of adult-type granulosa cell tumor of the ovary
A Färkkilä, UM Haltia, J Tapper, MK McConechy, DG Huntsman, ...
Annals of Medicine 49 (5), 435-447, 2017
Anti-Müllerian hormone inhibits growth of AMH type II receptor-positive human ovarian granulosa cell tumor cells by activating apoptosis
M Anttonen, A Färkkilä, H Tauriala, M Kauppinen, DT MacLaughlin, ...
Laboratory investigation 91 (11), 1605-1614, 2011
Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation
J Duraiswamy, R Turrini, A Minasyan, D Barras, I Crespo, AJ Grimm, ...
Cancer Cell 39 (12), 1623-1642. e20, 2021
Genetically defined syngeneic mouse models of ovarian cancer as tools for the discovery of combination immunotherapy
S Iyer, S Zhang, S Yucel, H Horn, SG Smith, F Reinhardt, E Hoefsmit, ...
Cancer Discovery 11 (2), 384-407, 2021
Clinical characteristics and survival of patients with an adult-type ovarian granulosa cell tumor: a 56-year single-center experience
S Bryk, A Färkkilä, R Bützow, A Leminen, M Heikinheimo, M Anttonen, ...
International Journal of Gynecologic Cancer 25 (1), 2015
FOXL2, GATA4, and SMAD3 co-operatively modulate gene expression, cell viability and apoptosis in ovarian granulosa cell tumor cells
M Anttonen, M Pihlajoki, N Andersson, A Georges, D L'hôte, S Vattulainen, ...
PLoS One 9 (1), e85545, 2014
Molecularly defined adult granulosa cell tumor of the ovary: the clinical phenotype
MK McConechy, A Färkkilä, HM Horlings, A Talhouk, L Unkila-Kallio, ...
Journal of the National Cancer Institute 108 (11), djw134, 2016
The clinical utility of serum anti‐M üllerian hormone in the follow‐up of ovarian adult‐type granulosa cell tumors—A comparative study with inhibin B
A Färkkilä, S Koskela, S Bryk, H Alfthan, R Bützow, A Leminen, U Puistola, ...
International Journal of Cancer 137 (7), 1661-1671, 2015
Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 are highly expressed in ovarian granulosa cell tumors
A Färkkilä, M Anttonen, J Pociuviene, A Leminen, R Butzow, ...
European journal of endocrinology 164 (1), 115-122, 2011
TERT promoter mutation in adult granulosa cell tumor of the ovary
JA Pilsworth, DR Cochrane, Z Xia, G Aubert, AEM Färkkilä, HM Horlings, ...
Modern Pathology 31 (7), 1107-1115, 2018
Characteristics and outcome of recurrence in molecularly defined adult-type ovarian granulosa cell tumors
S Bryk, A Färkkilä, R Bützow, A Leminen, J Tapper, M Heikinheimo, ...
Gynecologic Oncology 143 (3), 571-577, 2016
Mathematical modeling predicts response to chemotherapy and drug combinations in ovarian cancer
E Kozłowska, A Färkkilä, T Vallius, O Carpén, J Kemppainen, S Grénman, ...
Cancer research 78 (14), 4036-4044, 2018
The system can't perform the operation now. Try again later.
Articles 1–20